Hybrid method in severe pulmonary embolism not suitable for systemic fibrinolysis

Abstract

Acute massive pulmonary embolism is known to be associated with high mortality, and treatment options may be limited if systemic fibrinolysis is contraindicated. We report the exciting results of a novel mechanical-pharmacological hybrid approach in 3 patients with life-threatening massive pulmonary embolism, in whom systemic fibrinolysis was contraindicated.

Keywords

Fibrinolytic agents Pulmonary embolism Tissue plasminogen activator Thrombolytic therapy Ultrasonic therapy Vascular access devices

Get full access to this article

View all access options for this article.

References

Kucher

Rossi

De Rosa

Goldhaber

. Massive pulmonary embolism. Circulation 2006; 113: 577–582.

Cuculi

Kobza

Bergner

Erne

. Usefulness of aspiration of pulmonary emboli and prolonged local thrombolysis to treat pulmonary embolism. Am J Cardiol 2012; 110: 1841–1845.

Mehta

Cox

Smith

et al.

Race/ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke 2014; 45: 2263–2269.

Piazza

Hohlfelder

Jaff

et al.

A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II Study. JACC Cardiovasc Interv 2015; 8: 1382–1392.

Tapson VF, Piazza G, Sterling K, Ouriel K, Liu PY, Goldhaber SZ. Optimum duration and dose of r-tPA with the acoustic pulse thrombolysis procedure for submassive pulmonary embolism: OPTALYSE PE. Available at: www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2835. Accessed September 15, 2017.